~~<i id='4ED82012A8'><strike id='4ED82012A8'><tt id='4ED82012A8'><pre id='4ED82012A8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：focus 2025-08-28 13:04:05 - browse：79

An advisory panel to the Food and Drug Administration delivered a split decision on a surgical system used in a controversial blood pressure treatment called renal denervation.

The panel, whose advice the FDA typically follows, voted that the system developed by ReCor Medical was safe and effective. It voted that the benefits of a system developed by Medtronic, however, did not outweigh the risks.

“While this is a very safe procedure, the efficacy was mild at best,” Keith Allen, director of surgical research at St. Luke’s Hospital of Kansas City, said regarding Medtronic’s device.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Clinical trials must include more disabled people

focus

hotspot

focus

hotspot

AdobeThebodymassindexhaslongbeenslammedasabluntinstrumentforevaluatinghealth,evenmoresowithnewobesit

WSS

See how much Covid

BMI, flaws aside, is found to be useful estimate of body fat in youth

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Hilary expected to bring catastrophic, life

Congress must give Medicare recipients genetic counseling access

Hilary may become 1st tropical storm to make landfall in California in 84 years

focus

leisure time

focus

Virginia high school admissions case could be legal follow

Beware the threat of staffing cuts at the CDC

Malaria cases in Florida and Texas: Here’s what you need to know

FDA approves first treatment for ultra

Apple is now the first public company to be valued at $3 trillion

Baltimore teen accused of firing into crowd during block party mass shooting

How to save PrEP access — and even expand it

Let's speed up science by embracing open access publishing

Hepatitis C has a cure — but many Americans still lack access to it

Evacuations in place as 3 wildfires burn in eastern Washington state

hotspot

ASCO: AstraZeneca says CAR

As Maui death toll rises, number of missing remains unclear

Cancer drug shortages' outsize impact on ovarian cancer patients

Innovation in antibiotics is ailing. 'Brain drain' may kill it

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

focus

focus

hotspot

hotspot